At a glance:
Scientists mapped gene expression and cell behavior in response to perturbations such as changes in the microbiome and inflammation.
Findings point to remarkable regional structure across different segments within small and large intestine.
Approach represents new way to study cross talk between gut epithelial cells, structural cells, and immune system in disease and health.
The intestine maintains an exquisitely delicate balance in the body, absorbing nutrients and water while also ensuring a healthy relationship with the gut microbiome — the constellation of microorganisms that reside in the human gut, regulating its function in myriad ways that affect health and disease.
This precarious equilibrium can be disrupted in conditions such as celiac disease, ulcerative colitis, or Crohn’s disease, leading to aberrant immune response and inflammation. Yet scientists don’t fully understand how different regions of the intestine resist or adapt to changes in the environment and how disease disrupts that ability.
Now, Harvard Medical School researchers at the Broad Institute of MIT and Harvard and Massachusetts General Hospital have analyzed the entire mouse intestine, creating a map of gene expression and cell behavior by location in response to various perturbations such as microbiome changes, inflammation, and circadian rhythms.
The work reveals tight regulation of cell types and states in different regions of the organ, as well as a unique segment of the colon that is controlled by immune signals.
Authorship, funding, disclosures
Additional authors include Åsa Segerstolpe, Eric M. Brown, Rebecca Weisberg, Toru Nakata, Hiroshi Yano, Paula Herbst, David Artis, and Daniel B. Graham.
This work was supported in part by the Center for the Study of Inflammatory Bowel Disease, National Institutes of Health (grants RC2 DK135492, P30 DK043351, DK126871, AI151599, AI095466, AI095608, AR070116, AI172027, DK132244, K99AI180354), The Leona M. and Harry B. Helmsley Charitable Trust, Klarman Cell Observatory, Jill Roberts Institute for Research in IBD, Kenneth Rainin Foundation, Sanders Family Foundation, Rosanne H. Silbermann Foundation, Linda and Glenn Greenberg, and Allen Discovery Center Program, a Paul G. Allen Frontiers Group advised program of the Paul G. Allen Family Foundation.
Xavier is a co-founder of Jnana Therapeutics, board director at MoonLake Immunotherapeutics, and a consultant to Nestlé, and serves on the advisory board of Magnet Biomedicine. These organizations had no role in the study.